A new phase II clinical trial (NCT0463659) is exploring the safety and efficacy of almonertinib and concurrent thoracic radiotherapy in patients with unresectable stage III EGFR-mutated NSCLC (36). Here, EGFR is linked to non-small cell lung carcinoma.